Smith & Nephew

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics; Sports Medicine and ENT; and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies and ENT. The Advanced Wound Management segment comprises advanced wound care, advanced wound bioactives and advanced wound devices businesses. The company was founded by Thomas James Smith in 1856 and is headquartered in Watford, the United Kingdom.

Earnings data Q4 2019

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT. The Advanced Wound Management segment includes advanced wound care, advanced wound bioactives, and advanced wound devices businesses. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.

Designation recognizes Vizient-contracted products that bring improvements to healthcare industry LONDON , Jan. 30, 2023 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces that its LEAF Patient Monitoring System has received an Innovative Technology designation from Vizient, Inc., the largest healthcare performance improvement company in the United States. Smith+Nephew exhibited the LEAF Patient Monitoring System at the Vizient Innovative Technology Exchange on October 17th in Dallas, Texas.

Smith+Nephew receives Innovative Technology designation from Vizient for LEAF™ Patient Monitoring System

The medical device industry has undergone considerable consolidation in recent years, leaving a small number of competitors, and offers long-term growth potential due to increasing longevity, an aging population and an expanding middle class.

Smith & Nephew Is Reverting to Fair Value

Smith & Nephew plc (NYSE:SNN ) Q3 2022 Results Conference Call November 3, 2022 4:30 AM ET Company Participants Deepak Nath - Chief Executive Officer Anne-Francoise Nesmes - Chief Financial Officer Conference Call Participants Hassan Al-Wakeel - Barclays Jack Reynolds - RBC David Adlington - JPMorgan Julien Dormois - BNP Paribas Robert Davies - Morgan Stanley Chris Gretler - Credit Suisse Deepak Nath Good morning. Welcome to the Smith & Nephew Third Quarter Call.

Smith & Nephew plc (SNN) Q3 2022 Earnings Call Transcript

Smith & Nephew PLC (LSE:SN) reported a 4.8% increase in underlying revenue for the third quarter and forecast revenue growth for the full year in the middle of its previously guided range of 4%-5%.  The medical products company left its trading profit margin guidance for the year unchanged at around 17.5%, down from 18% in 2021.

Smith & Nephew says 'on track' to meet full-year revenue forecast

LONDON , Nov. 1, 2022 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the introduction of its JOURNEY II ROX Total Knee Solution – a reverse hybrid construct for total knee arthroplasty. This new procedural product solution aims to provide surgeons with the clinical advantage of an advanced bearing material and anatomic design combined with the efficiency1 and potential long-term tibia fixation of a cementless knee.

Smith+Nephew expands procedural innovation with introduction of JOURNEY™ II ROX™ Total Knee Solution

Smith & Nephew PLC (LSE:SN) shares reacted to reports from US medical technology companies that surgical procedure volumes are returning to pre-pandemic levels.

Smith & Nephew little boosted by rivals' reports of improving hip and knee sales

Medical devices manufacturer Smith & Nephew (S&N) has seen its shares sliding. I do not yet see the growth the company is targeting, but business has been recovering and its interim figures were decent if nothing special.

Smith & Nephew: Still A Buy Despite Short-Term Challenges

LONDON , Sept. 26, 2022 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the first cases for revision knee replacement utilizing its CORI◊ Surgical System.

Smith+Nephew first to market with revision knee indication on robotics platform

LONDON , Sept. 21, 2022 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it is expanding the reach of its medical education curriculum through a suite of advanced simulation technologies.

Smith+Nephew Academy expands global access to professional medical education through virtual reality and other advanced simulation technologies

LONDON , Sept. 14, 2022 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE: SNN), the global medical technology company, today announces promising new data furthering a number of published studies supporting the use of its REGENETEN Bioinductive Implant in rotator cuff repair.

New randomized controlled trial shows that addition of Smith+Nephew's REGENETEN™ Bioinductive Implant delivers 86% reduction in rotator cuff re-tear rates at 12 months

FTSE 100 constituent and medical equipment maker Smith & Nephew PLC ( SNN , Financial) ( LSE:SN. , Financial) seemed to be making progress after its 2021 results in February.

Smith & Nephew: A Medical Equipment Opportunity

LONDON , Aug. 4, 2022 /PRNewswire/ -- Smith+Nephew (LSE: SN) (NYSE: SNN), the global medical technology company, today announces that the OXINIUM Technology Tour of Change mobile exhibit will make a stop at the Pro Football Hall of Fame during its enshrinement weekend in Canton, Ohio from August 4-6. As the official joint replacement technology of the Pro Football Hall of Fame, Smith+Nephew is committed to educating retired players, their families, and the community about the differences in material, design and technology to consider when selecting a hip or knee replacement.

Smith+Nephew's OXINIUM™ Technology Tour of Change touches down at the Pro Football Hall of Fame during enshrinement weekend

Smith & Nephew plc (NYSE:SNN ) Q2 2022 Results Conference Call July 28, 2022 3:30 AM ET Company Participants Deepak Nath - Chief Executive Officer Anne-Francoise Nesmes - Chief Financial Officer Conference Call Participants Patrick Wood - Bank of America Jack Reynolds-Clark - RBC Hassan Al-Wakeel - Barclays Julien Dormois - BNP Paribas Chris Gretler - Credit Suisse David Adlington - JP Morgan Deepak Nath I'll just draw your attention to the safe harbor statement on the slide that's about to pop up in front of us. So, it's a pleasure to be reporting the results of my first full quarter as CEO and also to be meeting many of you in person for the first time.

Smith & Nephew plc (SNN) CEO Deepak Nath on Q2 2022 Results - Earnings Call Transcript

Shares in Smith & Nephew PLC (LSE:SN) plunged almost 10% after forecasting a drop in profit margins on the back of inflation and “external supply challenges". The British medical products maker now expects trading profit margin of 17.5% for 2022 compared to a 18% margin last year.

Smith & Nephew's shares slump as profit margins squeezed

LONDON , July 13, 2022 /PRNewswire/ -- Smith+Nephew (LSE: SN) (NYSE: SNN), the global medical technology company, today announces a robust line-up featuring several of its advanced joint repair solutions and a wide array of educational activities during the 2022 American Orthopaedic Society for Sport Medicine (AOSSM) Annual Meeting being held in Colorado Springs July 13-17. These include: The REGENETEN◊ Bioinductive Implant With the potential to address approximately 17 million people with rotator cuff disease in the US1, the REGENETEN implant provides a patient centric treatment that supports the body's natural healing response required to facilitate healing of rotator cuff tears.2-6  With 20+ publications7 to its name, among the most in its category, the REGENETEN implant has been shown in early studies to disrupt disease progression3-5,8, expedite return to normal activity8 and potentially reduce re-tears.9,10 The REGENETEN implant is part of Smith+Nephew's comprehensive Advanced Healing Solutions portfolio - redefining biological healing in rotator cuff repair along with expanded applications for Gluteus Medius and Achilles tears.

Smith+Nephew to showcase latest innovations for sports medicine joint repair at 2022 AOSSM Annual Meeting

LONDON , July 12, 2022 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of the WOUND COMPASS™ Clinical Support App. The WOUND COMPASS Clinical Support App is a comprehensive digital support tool for health care professionals that aids wound assessment and decision-making to help reduce practice variation.

Smith+Nephew launches Clinical Support App to help reduce practice variation in wound care

LONDON , June 30, 2022 /PRNewswire/ -- Smith+Nephew (LSE: SN), (NYSE: SNN), the global medical technology company, today announces the first robotic-assisted surgery using its LEGION CONCELOC Cementless Total Knee System was performed by Dr. Cyna Khalily, an orthopaedic surgeon specializing in adult reconstructive surgery of the hip and knee in Louisville, KY. Smith+Nephew is the only medical device company to offer both total and partial cementless knee implants, and now, a robotic-assisted solution for cementless total knee arthroplasty (TKA) with the CORI◊ Surgical System.

Smith+Nephew announces first robotic-assisted surgery using its LEGION™ CONCELOC™ Cementless Total Knee System

LONDON , June 14, 2022 /PRNewswire/ -- Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology business, announces the publication of a new peer-reviewed article in Wounds International . The article proposes that an estimated 3.5 billion hours of nursing time could be released globally by 2030 if shared care approaches between nurses and patients are adopted in chronic wound care alongside long-wear advanced foam dressings1.

SMITH+NEPHEW SHARES NEW RESEARCH THAT ESTIMATES 3.5 BILLION HOURS OF NURSE TIME COULD BE RELEASED BY 2030 THROUGH SHARED WOUND CARE AND USE OF LONG-WEAR ADVANCED FOAM DRESSINGS

LONDON , June 8, 2022 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces that the first total hip arthroplasty (THA) procedure using RI.HIP MODELER, a new preoperative spinopelvic assessment tool, was performed by Dr. Rhett Hallows at Duke Regional Hospital. Separately, Dr. Thorsten Seyler performed the first-ever RI.HIP NAVIGATION procedure on the CORI Surgical System at Duke University in April.

Smith+Nephew announces first total hip replacement cases on its CORI™ Surgical System using RI.HIP MODELER and RI.HIP NAVIGATION

Oxford BioMedica PLC (AIM:OXB), Smith & Nephew PLC (LSE:SN) and Spire Healthcare Group Plc (LSE:SPI) are among UK midcap health-care companies 'vulnerable” to takeovers from private-equity (PE) firms, investment bank RBC Group says. The stocks trade below historical multiples and have under-geared balance sheets - making them ripe for "PE firms seemingly well-funded and large trade players having strong balance sheets, and in some cases post-COVID earnings holes to fill," according to the bank.

Oxford Biomedica, Smith & Nephew 'vulnerable' to takeover

LUGANO, Switzerland--(BUSINESS WIRE)-- #celltherapy--Healiva®, a patient-centric company delivering life-enhancing precision medicine for patients with chronic and acute wounds, announced today the acquisition of two innovative cell therapy assets from Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business. The acquisition enables Healiva® to establish one of the world's broadest portfolios of affordable, personalized, end-to-end wound care consisting of enzyme technology, autologous & al

Healiva® Acquires Two Wound-healing Cell Therapy Assets From Smith+Nephew

Smith & Nephew has seen its business performance turn the corner post-pandemic and I expect future growth. The share price has crept up slightly but I continue to see long-term value here.

Smith & Nephew: Fair Price For An Attractive Medical Devices Supplier

Smith & Nephew PLC (NYSE: SNN) posted Q1 revenue of $1.31 billion, up 3.3% on a reported basis (including -2.6% currency effect) and up 5.9% on an underlying basis. Sports Medicine & ENT revenue up 8.6% underlying.

Smith & Nephew Posts Q1 Sales Growth As Elective Procedures Rebound

Smith & Nephew PLC (LSE:SN) (Smith & Nephew PLC (LSE:SN)) said a recovery in elective surgery and good sports demand would keep it on track to hit its targets in 2022. Revenue in the first quarter rose 3.3% on a reported basis to US$1.3bn for the quarter ended April 2, up from US$1.26bn a year ago.

Smith & Nephew revenues jump as elective procedure volumes rebound

LONDON , March 31, 2022 /PRNewswire/ -- Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology business, announces the publication of a peer-reviewed study in the Advances in Wound Care Journal reporting outcomes for Medicare patients with a diabetic foot ulcer (DFU) that shows GRAFIX Cryopreserved Placental Membrane cut DFU recurrence rates in half compared to leading cellular and tissue-based product (CTP) competitors.1 ( Link to publication ). DFUs affect 3 million people annually in the US, and Medicare spending for the treatment of DFUs has been estimated to be $6-18 billion annually.2 This study reviewed over 1.3 million Medicare patients with lower limb chronic ulcers, and analyzed 7,849 claims for patients treated between 2013 and 2017 in an outpatient setting who presented with a DFU and received a CTP.

News for Smith & Nephew Stock (SNN)